Literature DB >> 10447258

Identification of a common PEX1 mutation in Zellweger syndrome.

C S Collins1, S J Gould.   

Abstract

The Zellweger spectrum of disease, encompassing Zellweger syndrome and the progressively milder phenotypes of neonatal adrenoleukodystrophy and infantile Refsum disease, is due to a failure to form functional peroxisomes. Cell fusion complementation studies demonstrated that these diseases are genetically heterogeneous, with two-thirds of all patients lying within a single complementation group, CG1. Molecular genetic and cell biology studies have shown that PEX1 is deficient in many CG1 patients. However, previous studies have focused on mildly affected patients and there is still no report of two mutant PEX1 alleles in any Zellweger syndrome patient. Furthermore, mutations in the PMP70 gene have also been identified in two Zellweger syndrome patients from CG1, raising the possibility that CG1 patients may represent a mixture of PEX1-deficient and PMP70-deficient individuals. To address the molecular basis of disease in Zellweger syndrome patients from CG1, we examined all 24 PEX1 exons in four patients, including both patients that have mutations in PMP70. PEX1 mutations were detected in all four patients, including a 1-bp insertion (c.2097insT) in exon 13 that was present in three of the four patients. Subsequent studies demonstrated that this mutation is present in one-half of all CG1 patients and correlates with the Zellweger syndrome phenotype. As this mutation leads to a loss of protein function its frequency makes it the most common cause of Zellweger syndrome, helping to explain the high percentage of patients that belong to CG1.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10447258     DOI: 10.1002/(SICI)1098-1004(1999)14:1<45::AID-HUMU6>3.0.CO;2-J

Source DB:  PubMed          Journal:  Hum Mutat        ISSN: 1059-7794            Impact factor:   4.878


  16 in total

Review 1.  Disorders related to peroxisomal membranes.

Authors:  J Gärtner
Journal:  J Inherit Metab Dis       Date:  2000-05       Impact factor: 4.982

2.  The Pex1-G844D mouse: a model for mild human Zellweger spectrum disorder.

Authors:  Shandi Hiebler; Tomohiro Masuda; Joseph G Hacia; Ann B Moser; Phyllis L Faust; Anita Liu; Nivedita Chowdhury; Ning Huang; Amanda Lauer; Jean Bennett; Paul A Watkins; Donald J Zack; Nancy E Braverman; Gerald V Raymond; Steven J Steinberg
Journal:  Mol Genet Metab       Date:  2014-01-23       Impact factor: 4.797

3.  Infection-Induced Peroxisome Biogenesis Is a Metabolic Strategy for Herpesvirus Replication.

Authors:  Pierre M Jean Beltran; Katelyn C Cook; Yutaka Hashimoto; Cyril Galitzine; Laura A Murray; Olga Vitek; Ileana M Cristea
Journal:  Cell Host Microbe       Date:  2018-09-27       Impact factor: 21.023

4.  Recovery of PEX1-Gly843Asp peroxisome dysfunction by small-molecule compounds.

Authors:  Rui Zhang; Li Chen; Sarn Jiralerspong; Ann Snowden; Steven Steinberg; Nancy Braverman
Journal:  Proc Natl Acad Sci U S A       Date:  2010-03-08       Impact factor: 11.205

5.  Disease specific therapies in leukodystrophies and leukoencephalopathies.

Authors:  Guy Helman; Keith Van Haren; Joshua L Bonkowsky; Genevieve Bernard; Amy Pizzino; Nancy Braverman; Dean Suhr; Marc C Patterson; S Ali Fatemi; Jeff Leonard; Marjo S van der Knaap; Stephen A Back; Stephen Damiani; Steven A Goldman; Asako Takanohashi; Magdalena Petryniak; David Rowitch; Albee Messing; Lawrence Wrabetz; Raphael Schiffmann; Florian Eichler; Maria L Escolar; Adeline Vanderver
Journal:  Mol Genet Metab       Date:  2015-02-07       Impact factor: 4.797

6.  PEX13 is mutated in complementation group 13 of the peroxisome-biogenesis disorders.

Authors:  Y Liu; J Björkman; A Urquhart; R J Wanders; D I Crane; S J Gould
Journal:  Am J Hum Genet       Date:  1999-09       Impact factor: 11.025

Review 7.  Emerging treatments for pediatric leukodystrophies.

Authors:  Guy Helman; Keith Van Haren; Maria L Escolar; Adeline Vanderver
Journal:  Pediatr Clin North Am       Date:  2015-04-08       Impact factor: 3.278

8.  Disorders of peroxisome biogenesis due to mutations in PEX1: phenotypes and PEX1 protein levels.

Authors:  C Walter; J Gootjes; P A Mooijer; H Portsteffen; C Klein; H R Waterham; P G Barth; J T Epplen; W H Kunau; R J Wanders; G Dodt
Journal:  Am J Hum Genet       Date:  2001-06-01       Impact factor: 11.025

9.  Identification of novel mutations and sequence variation in the Zellweger syndrome spectrum of peroxisome biogenesis disorders.

Authors:  Wing Yan Yik; Steven J Steinberg; Ann B Moser; Hugo W Moser; Joseph G Hacia
Journal:  Hum Mutat       Date:  2009-03       Impact factor: 4.878

Review 10.  Mammalian peroxisomal ABC transporters: from endogenous substrates to pathology and clinical significance.

Authors:  Stephan Kemp; Frederica L Theodoulou; Ronald J A Wanders
Journal:  Br J Pharmacol       Date:  2011-12       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.